

Proportion of Hospitalizations Preventable with Increased Oral SARS-CoV-2 Antiviral Treatment

Authors: Matthew E. Levy, PhD¹; Vanessa Chilunda, PhD¹; Phillip R. Heaton, PhD²;
Joseph Grzymiski, PhD^{3,4}; Pamala A. Pawloski, PharmD⁵; Jason D. Goldman, MD,
MPH^{6,7,8}; Shishi Luo, PhD¹

¹Helix, San Mateo, California; ²Department of Pathology and Laboratory Medicine, HealthPartners, Bloomington, Minnesota; ³Department of Internal Medicine, University of Nevada Reno, School of Medicine, Reno, Nevada; ⁴Renown Health, Reno, Nevada; ⁵HealthPartners Institute, Minneapolis, Minnesota; ⁶Providence St. Joseph Health System, Renton, Washington; ⁷Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, Washington; ⁸Division of Infectious Disease, University of Washington, Seattle, Washington

Corresponding author: Matthew Levy, PhD. Helix. Mail: 101 S. Ellsworth Avenue, Suite 350, San Mateo, CA 94401. Phone: 631-903-3709. Email: matt.levy@helix.com.

Abstract

We estimated the proportion of hospitalizations that could have been averted had all eligible high-risk adults with SARS-CoV-2 infection in a clinical cohort been treated with an oral SARS-CoV-2 antiviral agent early in infection. Among 3,037 patients with risk factors for progressing to severe COVID-19, 946 (31.1%) received an oral antiviral prescription (834 nirmatrelvir and 112 molnupiravir). Only 3.0% of treated patients vs 9.1% of untreated patients were hospitalized (adjusted risk ratio [RR]=0.27; 95% confidence interval [CI]: 0.18-0.41). If all patients had been treated, an estimated 63.3% (95% CI: 50.4-75.1) of hospitalizations within 30 days could have been prevented. This finding is attributed to large gaps in treatment and a strong protective association of antiviral treatment with subsequent hospitalization.

Introduction

The oral SARS-CoV-2 antiviral agents nirmatrelvir (plus ritonavir) and molnupiravir are effective at preventing COVID-19-associated hospitalization.^{1,2} However, prescribing gaps exist among nonhospitalized SARS-CoV-2-infected patients with risk factors for progressing to severe COVID-19.³ To demonstrate the potential impact of improving guideline-concordant oral antiviral prescribing, we estimated the proportion of hospitalizations that could have been averted had all eligible individuals in a clinical cohort been treated early in infection.

Methods

We performed a retrospective analysis of electronic health record data obtained from two health systems: HealthPartners (Minnesota and Wisconsin) and Renown Health (Nevada). This analysis included adults aged ≥ 18 years with a positive health system-administered SARS-CoV-2 test (molecular or antigen) between April 2022-June 2023 who had ≥ 1 outpatient visit in the preceding year and ≥ 1 risk factor for severe COVID-19 (≥ 50 years old, unvaccinated, or ≥ 1 high-risk condition).⁴ Detailed methods are provided in eMethods and eTables 1-3.

The index date was the collection date of each patient's first positive test. All-cause hospitalization was defined as admission 0-30 days after the index date. Patients first tested on the date of hospitalization were included to minimize selection bias. Treatment was defined as receiving a prescription for nirmatrelvir or molnupiravir within 14 days before through 5 days after the index date (and, if hospitalized, ≥ 1 day pre-admission).

Patients with hospitalizations 1-30 days earlier or with outpatient remdesivir or SARS-CoV-2 monoclonal antibody treatment were excluded.

Modified Poisson regression was employed to estimate adjusted risk ratios (RRs) for the association between treatment and hospitalization, overall and within demographic and clinical subgroups.⁵ Applying the formula for population attributable fraction to the comparison of no treatment vs treatment ($p_c \times \frac{RR_{no\ treatment} - 1}{RR_{no\ treatment}}$, where p_c is the proportion of hospitalized cases who had not been treated), we estimated the 'preventable fraction'—the proportion of hospitalizations that could be prevented if all persons were treated.⁶ Confidence intervals (CIs) were computed using the 2.5th and 97.5th percentiles from 1000 bootstrap resampling iterations. Analyses were performed using R v4.2.3.

Results

Among 3,037 SARS-CoV-2-infected patients with risk factors for severe COVID-19, 35.7% were ≥ 65 years old, 20.9% were unvaccinated, 12.8% were immunocompromised, and 11.8% had Charlson comorbidity index (CCI) scores ≥ 3 (Table 1). Overall, 946 (31.1%) received oral antiviral prescriptions (834 nirmatrelvir; 112 molnupiravir).

Only 3.0% of treated patients vs 9.1% of untreated patients were hospitalized (Table 2). Among 218 hospitalizations, 163 (74.8%) occurred on the date of SARS-CoV-2 testing. After adjustment, treatment was associated with reduced risk of hospitalization for any oral antiviral agent (RR=0.27; 95% CI: 0.18-0.41), nirmatrelvir (RR=0.36; CI: 0.22-0.58), and molnupiravir (RR=0.22; CI: 0.08-0.59). The association for any treatment was

stronger in patients aged ≥ 65 (RR=0.15) vs 18-49 (RR=0.48) years (interaction, $p < 0.001$).

If all patients had been treated, an estimated 63.3% (95% CI: 50.4-75.1) of hospitalizations could have been averted (Table 2). The preventable fraction was similarly high in subgroups who were older (≥ 65 years) (78.2%; CI: 64.8-89.9), unvaccinated (73.6%; CI: 55.1-91.3), immunocompromised (68.1%; CI: 48.1-89.7), or with multimorbidity (CCI ≥ 3) (77.5%; CI: 61.8-92.8).

Discussion

Among patients testing positive for SARS-CoV-2 with high risk for COVID-19 progression, the majority of hospitalizations within 30 days could have been prevented if all patients had received early antiviral treatment. This finding is attributed to large gaps in treatment and a strong protective association of antiviral treatment with subsequent hospitalization. Given that many hospitalizations occurred on the date of testing, underutilization of outpatient testing or limited access to treatment upon onset of symptoms may be an additional contributing factor to underuse of antivirals. Study limitations include the inability to confirm symptomatic COVID-19, lack of data on timing of symptom onset and causes of hospitalization, and reliance on prescriptions for defining antiviral treatment.

Acknowledgements

Conflict of Interest Disclosures: Drs. Levy, Chilunda, and Luo are employees of Helix, Inc. Drs. Levy and Luo report contracted research from Pfizer and the Centers for Disease Control and Prevention (CDC). Dr. Levy reports contracted research and travel support from Novavax. Dr. Heaton reports contracted research from Seegene USA and Helix, Inc. Dr. Grzymiski is employed by the University of Nevada, Reno and Renown Health, and reports a professional relationship with the Desert Research Institute and research funding from Gilead Sciences and the National Institute of Environmental Health Sciences (NIEHS). Dr. Goldman reports contracted research from Helix, Gilead, Eli Lilly, and Regeneron, grants from Merck (BARDA) and Gilead, and collaborative services agreements with Adaptive Biotechnologies, Monogram Biosciences and LabCorp; and serving as a speaker or advisory board member for Gilead and Eli Lilly. Dr. Luo reports patents pending or issued to Helix, Inc. No other disclosures are reported.

Funding/Support: This work was supported by Helix, HealthPartners, the Nevada Governor's Office of Economic Development, Renown Health, and the Renown Health Foundation.

Role of the Funder/Sponsor: Helix was involved in the design and conduct of the study. Helix, HealthPartners, and Renown Health were involved in the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We acknowledge the Helix Clinical Informatics and Bioinformatics teams for their contributions to electronic health record data and viral sequencing pipelines. We also acknowledge Catherine Clinton for her oversight and guidance in ensuring research compliance. We thank HealthPartners, Renown Health, and the Desert Research Institute for helping to launch the Helix Cohorts, and we thank all collaborators and research participants within the ViEW Network™, Healthy Nevada Project, and myGenetics protocols.

References

1. Lin DY, Abi Fadel F, Huang S, et al. Nirmatrelvir or molnupiravir use and severe outcomes from omicron infections. *JAMA Netw Open*. 2023;6(9):e2335077. doi:10.1001/jamanetworkopen.2023.35077
2. Paraskevis D, Gkova M, Mellou K, et al. Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients. *J Infect Dis*. Published online August 11, 2023. doi:10.1093/infdis/jiad324
3. Yan L, Streja E, Li Y, et al. Anti-SARS-CoV-2 Pharmacotherapies among nonhospitalized US veterans, January 2022 to January 2023. *JAMA Netw Open*. 2023;6(8):e2331249. doi:10.1001/jamanetworkopen.2023.31249
4. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. Centers for Disease Control and Prevention. Updated February 9, 2023. Accessed November 27, 2023. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html>
5. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol*. 2004;159(7):702-706. doi:10.1093/aje/kwh090
6. Khosravi A, Nazemipour M, Shinozaki T, Mansournia MA. Population attributable fraction in textbooks: time to revise. *Global Epidemiol*. 2021;3:100062. doi:10.1016/j.gloepi.2021.100062

Table 1. Patient Characteristics Overall and Stratified by Oral SARS-CoV-2

Antiviral Treatment Status.

Characteristic	Overall (n=3,037), No. (%)	Treatment status		
		Not treated (n=2,091), No. (%)	Treated with nirmatrelvir ^a (n=834), No. (%)	Treated with molnupiravir (n=112), No. (%)
Age group				
18 to 49 y	1,101 (36.3)	836 (40.0)	236 (28.3)	29 (25.9)
50 to 64 y	852 (28.1)	564 (27.0)	259 (31.1)	29 (25.9)
≥65 y	1,084 (35.7)	691 (33.0)	339 (40.6)	54 (48.2)
Female	2,102 (69.2)	1,436 (68.7)	596 (71.5)	70 (62.5)
Race and ethnicity				
Asian, non-Hispanic	117 (3.9)	81 (3.9)	33 (4.0)	3 (2.7)
Black, non-Hispanic	173 (5.7)	124 (5.9)	44 (5.3)	5 (4.5)
Hispanic	98 (3.2)	79 (3.8)	17 (2.0)	2 (1.8)
White, non-Hispanic	2,539 (83.6)	1,729 (82.7)	711 (85.3)	99 (88.4)
Other or unknown	110 (3.6)	78 (3.7)	29 (3.5)	3 (2.7)
SARS-CoV-2 vaccination ^b				
Vaccinated 0-5 mo earlier	1,109 (36.5)	731 (35.0)	323 (38.7)	55 (49.1)
Vaccinated 6-11 mo earlier	801 (26.4)	568 (27.2)	208 (24.9)	25 (22.3)
Vaccinated ≥12 mo earlier	492 (16.2)	349 (16.7)	126 (15.1)	17 (15.2)
Unvaccinated	635 (20.9)	443 (21.2)	177 (21.2)	15 (13.4)
Potential moderate or severe nirmatrelvir/ritonavir drug-drug interaction	437 (14.4)	300 (14.3)	107 (12.8)	30 (26.8)
Underlying medical conditions				
Asthma	511 (16.8)	304 (14.5)	181 (21.7)	26 (23.2)
Chronic lung disease	258 (8.5)	170 (8.1)	68 (8.2)	20 (17.9)
Cardiovascular disease	613 (20.2)	405 (19.4)	159 (19.1)	49 (43.8)
Diabetes	459 (15.1)	278 (13.3)	155 (18.6)	26 (23.2)
Solid malignancy	287 (9.5)	200 (9.6)	77 (9.2)	10 (8.9)
Chronic kidney disease	209 (6.9)	148 (7.1)	42 (5.0)	19 (17.0)
Immunocompromised ^c	390 (12.8)	252 (12.1)	112 (13.4)	26 (23.2)
Charlson comorbidity index				
0	1,568 (51.6)	1,166 (55.8)	369 (44.2)	33 (29.5)
1-2	1,110 (36.5)	688 (32.9)	373 (44.7)	49 (43.8)
3-4	258 (8.5)	156 (7.5)	77 (9.2)	25 (22.3)
≥5	101 (3.3)	81 (3.9)	15 (1.8)	5 (4.5)

^a In combination with ritonavir.

^b Defined by whether there was ≥1 SARS-CoV-2 vaccine record prior to the specimen collection date as well as by the duration of time since the most recent dose.

^c Defined as hematologic malignancy (40), HIV (8), other intrinsic immune disorder (147), solid organ or stem cell transplantation (14), or use of immunosuppressive therapy in the prior six months (231).

Table 2. Association of Oral SARS-CoV-2 Antiviral Treatment with Hospitalization and the Preventable Fraction.

Subgroup	Not treated		Treated		% treated among hospitalized	Adjusted RR ^a (95% CI)	Preventable fraction, % (95% CI)
	Total	Hospitalized, No. (%)	Total	Hospitalized, No. (%)			
Overall	2,091	190 (9.1%)	946	28 (3.0%)	12.8%	0.27 (0.18-0.41)	63.3% (50.4-75.1)
By oral antiviral agent							
Nirmatrelvir ^b	1,775	105 (5.9%)	722	21 (2.9%)	—	0.36 (0.22-0.58) ^b	—
Molnupiravir ^c	2,041	185 (9.1%)	111	4 (3.6%)	—	0.22 (0.08-0.59) ^c	—
By age group							
18 to 49 y	836	35 (4.2%)	265	10 (3.8%)	22.2%	0.48 (0.18-1.30)	40.7% (-8.5-76.0)
50 to 64 y	564	31 (5.5%)	288	8 (2.8%)	20.5%	0.38 (0.15-0.94)	49.7% (11.0-80.4)
≥65 y	691	124 (17.9%)	393	10 (2.5%)	7.5%	0.15 (0.08-0.29)	78.2% (65.4-89.9)
By SARS-CoV-2 vaccination							
Vaccinated	1,648	122 (7.4%)	754	21 (2.8%)	14.7%	0.32 (0.20-0.51)	58.4% (41.6-73.4)
Unvaccinated	443	68 (15.3%)	192	7 (3.6%)	9.3%	0.19 (0.08-0.42)	73.6% (55.1-91.3)
By immunocompromised status							
Not immunocompromised	1,839	138 (7.5%)	808	21 (2.6%)	13.2%	0.28 (0.17-0.45)	62.4% (45.8-76.9)
Immunocompromised	252	52 (20.6%)	138	7 (5.1%)	11.9%	0.23 (0.10-0.51)	68.1% (48.1-89.7)
By underlying medical condition							
Asthma	304	34 (11.2%)	207	7 (3.4%)	17.1%	0.23 (0.09-0.59)	64.0% (37.2-89.1)
Chronic lung disease	170	38 (22.4%)	88	6 (6.8%)	13.6%	0.35 (0.13-0.98)	55.8% (9.8-88.8)
Cardiovascular disease	405	91 (22.5%)	208	8 (3.8%)	8.1%	0.16 (0.08-0.33)	76.9% (61.3-90.5)
Diabetes	278	45 (16.2%)	181	9 (5.0%)	16.7%	0.28 (0.13-0.58)	60.0% (35.3-83.8)
Solid malignancy	200	43 (21.5%)	87	6 (6.9%)	12.2%	0.29 (0.12-0.72)	61.9% (33.4-89.2)
Chronic kidney disease	148	47 (31.8%)	61	3 (4.9%)	6.0%	0.16 (0.05-0.53)	78.9% (59.7-100.0)
By Charlson comorbidity index							
0	1,166	43 (3.7%)	402	8 (2.0%)	15.7%	0.31 (0.14-0.71)	57.8% (29.4-82.8)
1-2	688	66 (9.6%)	422	13 (3.1%)	16.5%	0.31 (0.17-0.57)	57.8% (36.4-77.3)
≥3	237	81 (34.2%)	122	7 (5.7%)	8.0%	0.16 (0.07-0.35)	77.5% (61.8-92.8)

Abbreviations: CI, confidence interval; RR, risk ratio.

^a Adjusted for health system, age group (18 to 49, 50 to 64, 65 to 74, or ≥75 years), sex, race and ethnicity, specimen collection date (days since April 1, 2022, as a natural cubic spline with 4 degrees of freedom), SARS-CoV-2 vaccination history (vaccinated 0-5 mo earlier, vaccinated 6-11

mo earlier, vaccinated ≥ 12 mo earlier, or unvaccinated), smoking history (ever vs never), immunocompromised status, asthma, chronic lung disease, cardiovascular disease, cerebrovascular disease, diabetes, obesity, solid malignancy, chronic kidney disease, liver disease, and mental health disorder.

^b The analysis for nirmatrelvir (in combination with ritonavir) excluded patients with molnupiravir treatment (112) and patients with contraindications (462), including potential moderate or severe drug-drug interactions (437), severe renal impairment (25), and severe hepatic impairment (15). This exclusion resulted in the removal of 112 patients who were prescribed nirmatrelvir. When including all patients with contraindications, the adjusted RR=0.29 (95% CI: 0.19-0.44).

^c The analysis for molnupiravir excluded patients with nirmatrelvir treatment (834) and patients with documented pregnancy in the prior nine months (61). This exclusion resulted in the removal of one patient who was prescribed molnupiravir. When including pregnant persons, the adjusted RR=0.21 (95% CI: 0.08-0.56).